Novo Nordisk's Wegovy pill gains strong early uptake in US launch
Updated
Updated · CNBC · May 4
Novo Nordisk's Wegovy pill gains strong early uptake in US launch
14 articles · Updated · CNBC · May 4
Since January, tens of thousands have started the pill in the US, mostly new GLP-1 users, while LifeMD said daily new patients jumped from 300-400 to 600-1,000.
The rollout has challenged expectations that Eli Lilly would dominate oral GLP-1s; Lilly says more than 20,000 people started Foundayo in its first weeks, with over 1,000 daily starts.
Investors now await Novo's first-quarter results for clearer sales data, as the company weighs overseas expansion, manufacturing investment in Ireland and pressure from generic competition to injectable Wegovy.
Wegovy vs. Foundayo: Will patients ultimately choose higher weight loss or the convenience of a simpler daily pill?
As weight-loss pills go mainstream, what are the unforeseen consequences for our healthcare system and food industry?
Foundayo's April 2026 Launch: Prescription Growth, Market Access, and Competitive Edge vs. Wegovy
Overview
Eli Lilly launched Foundayo, an oral obesity drug, in April 2026 following FDA approval, entering a market where Novo Nordisk's Wegovy had a three-month head start. While Wegovy shows slightly greater weight loss and cardiovascular benefits, Foundayo offers flexible dosing without food or timing restrictions, expanding patient access and potentially improving adherence. Lilly supports Foundayo with a direct-to-consumer strategy, partnerships like Amazon Pharmacy, and significant manufacturing investments. Despite safety warnings and insurance coverage challenges, Lilly’s volume-driven pricing and broad retail availability aim to overcome barriers. The evolving market faces growing competition, pricing pressures, and regulatory uncertainties, with long-term success hinging on balancing efficacy, convenience, and access.